Cycle
2 products tracked · names used in filings: Cycle, Cycle Pharmaceuticals (Europe) Ltd
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 29 May 2026🇺🇸 FDA approval
FDA approves Cavhanza (nilotinib): new formulation or manufacturer
Cycle; NDA217379; New formulation or manufacturer; tablet, orally disintegrating · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Cavhanza nilotinib | Approved | 2026-05-29 |
| 🇪🇺 | Nityr nitisinone | Authorised | 2018-07-26 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.